drugset / Trial / NCT00113750

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

NCT00113750 ↗

Phase 2 Completed 70 enrolled Allergy Therapeutics
RandomizedParallel-groupSingle-blindTreatment

Summary

Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch, alder, and hazel) pollen. Different doses of Tree MATA will be administered and immunological changes following this treatment will be assessed.

Timeline

Start
2005-07
Primary completion
—
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tree MATA MPL Other / unclassified — Subcutaneous